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Meningeal tumors represent approximately 10–25% of primary brain tumors and occur
usually in elderly female patients. Most meningiomas are benign (80–85%) and for
symptomatic and/or large tumors, surgery, with or without radiation therapy (RT), has
been long established as an effective means of local tumor control. RT can be delivered to
inoperable lesions or to those with non-benign histology and for Simpson I–III and IV–V
resection. RT can be delivered with photons or particles (protons or carbon ions) in
stereotactic or non-stereotactic conditions. Particle therapy delivered for these tumors
uses the physical properties of charged carbon ions or protons to spare normal brain
tissue (i.e. Bragg peak), with or without or a dose-escalation paradigm for non-benign
lesions. PT can substantially decrease the dose delivered to the non-target brain tissues,
including but not limited to the hippocampi, optic apparatus or cochlea. Only a limited
number of meningioma patients have been treated with PT in the adjuvant or recurrent
setting, as well as for inoperable lesions with pencil beam scanning and with protons only.
Approximately 500 patients with image-defined or WHO grade I meningioma have been
treated with protons. The reported outcome, usually 5-year local tumor control, ranges
from 85 to 99% (median, 96%). For WHO grade II or III patients, the outcome of only 97
patients has been published, reporting a median tumor local control rate of 52% (range,
38–71.1). Only 24 recurring patients treated previously with photon radiotherapy and re-
treated with PT were reported. The clinical outcome of these challenging patients seems
interesting, provided that they presented initially with benign tumors, are not in the elderly
category and have been treated previously with conventional radiation dose of photons.
Overall, the number of meningioma patients treated or-re-irradiated with this treatment
modality is small and the clinical evidence level is somewhat low (i.e. 3b–5). In this review,
we detail the results of upfront PT delivered to patients with meningioma in the adjuvant
setting and for inoperable tumors. The outcome of meningioma patients treated with this
radiation modality for recurrent tumors, with or without previous RT, will also be reviewed.
Keywords: meningioma, proton therapy, recurrent disease, primary treatment, reirradiation, pencil beam scanned
proton therapy, surgeryDecember 2020 | Volume 10 | Article 5588451
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Meningiomas are the commonest primary brain tumor and
account for 10–25% of all cases (1). The WHO classification
describes three different histological grades: WHO grade I
meningioma account for up to 80% of cases and have a low
recurrence rate; WHO grade II comprise approximately 20–30%
of cases and have a recurrence rate of ~30–40%; and grade III
meningioma comprise around 1–2% and invariably recur (2).
Asymptomatic and incidental meningiomas do not usually
require active treatment and can be safely monitored (3, 4).
However, for symptomatic or growing tumors, surgery is still the
primary treatment modality, can achieve long-term tumor
control and in some cases can be curative (5). However,
despite advances in surgical techniques not all meningioma
are appropriate for surgery (e.g. due to anatomical location)
nor are all meningioma amenable to complete resection (e.g.
due to proximity to critical neurovascular structures or
tumor consistency). Furthermore, even when meningiomas are
completely resected, recurrence can still occur. In meningiomas
that recur, surgery is more challenging due to scar tissue, and is
associated with higher rates of morbidity and mortality. Recently
several integrated molecular models to predict the risk of
recurrence risk have been developed (6, 7), which, once
prospectively validated prospectively, could be used to guide to
the use of adjuvant radiotherapy. Due to the risk of recurrence,
radiotherapy has a clear role in the management of meningioma
in order to achieve durable, long-term control. It is used in the
adjuvant setting for most malignant meningioma, for some atypical
meningioma and for the occasional benign meningioma.
Currently the standard modality is fractionated external beam
radiotherapy with photons or radiosurgery for small tumors that
are not in direct vicinity of critical structures. The expansion of
proton beam facilities has led to increased use of this modality.
The main difference between photons, delivered in stereotactic-
or non-stereotactic condition, and protons is the remarkable
dose distribution obtained with the latter, where the dose is
delivered at a narrow area at the distal end of the proton
trajectory (i.e. the Bragg Peak). For small target volumes, it
may be questionable if proton therapy (PT) delivered with a
Gantry obtains a better dose distribution than radiosurgery (8),
for larger tumors, for which this latter treatment modality is not
an option, protons usually always achieve an improved dose-
conformation when compared to photons. The aim of this review
is to describe the contemporary experience of using PT for the
treatment of intracranial benign- and non-benign meningioma.PROTON THERAPY FOR BRAIN TUMORS
The dose deposition in tissue of proton beams is described by a
sharply defined Bragg peak, where the bulk of the dose is
deposited; beyond the peak the deposited dose drops to zero
within a few millimeters (9) (Figure 1). The maximum depth
(proton range) depends only on the initial energy of the proton
beams. The resulting PT dose distributions present both superiorFrontiers in Oncology | www.frontiersin.org 2dose conformality and lower total integral dose when compared
to the photon ones. Intensity Modulated Proton Therapy
(IMPT) technique (10), available for Pencil Beam Scanning
(PBS) systems, can achieve particularly steep dose gradients,
thus increasing furthermore the PT advantages. Brain tumors,
including meningiomas, typically located in close proximity to
many critical organs at risk (OAR), can clearly benefit from PT
dose conformality and healthy tissue sparing (11). This rationale
is further supported by the dose-dependent relationship for
many radiation induced toxicities which develop after RT for
brain tumors. This is the case, for instance, of dose to the
hippocampus which correlates with memory outcomes (12)
and dose to the hypothalamus and pituitary which correlates
with the severity of endocrine dysfunction (13). The increased
OAR dose sparing and integral dose reduction typical of PT is
even more crucial in cases of re-irradiation where PT is
frequently the only possible treatment modality. Figure 2
details such a case treated at the Paul Scherrer Institute with
52.2 GyRBE administered after a photon irradiation for tumor
recurrence. Of note, the second irradiation with protons could
completely spare the contralateral temporal lobe and optic nerve
(Figure 2). As shown in the dose–volume histogram (Figure 2),
PT enabled complete sparing of the initial target volume (i.e. pre-
irradiated Isodose line 100%) treated with photons and thus
made re-irradiation possible. Many factors such as the tumor
location (14), size and shape of the target volumes influence the
magnitude of the PT dosimetric advantages compared to
photons. A very recent study (15) for skull base meningiomas,
comparing VMAT, IMRT and IMPT reported a significant mean
dose reduction up to 48% for the bilateral hippocampi for IMPT
as compared to VMAT. Similar differences were found when
comparing mean dose to the normal brain tissue; the comparison
between IMRT and IMPT resulted in even larger differences in
dose to OAR, thus possibly leading to a clinically relevant
reduction of late neurocognitive side effects.FIGURE 1 | Typical depth dose curve in water for a clinical 170 MeV proton
beam used to treat intracranial meningioma.December 2020 | Volume 10 | Article 558845
Weber et al. Managing Meningioma With Proton TherapyPT can be administered to meningioma patients with several
delivery paradigms. Historically, protons were delivered with a
passive scattering system with which the distal end of the proton
tracks are controlled/modulated through the use of compensators
and the lateral aspect of the proton beam is shaped by brass
apertures. In contrast, spot-scanning PT, or as it is called
currently pencil beam scanning (PBS) PT, pristine proton pencil
beams are scanned in the target volume with different energies to
achieve the wanted depth dose distributions. This is in essence a
discrete way of administering dose using a ‘step and shoot’
paradigm. A US group has shown that PBS achieved a better
cochlear and lens sparing when compared to passive scattering
delivery in brain tumor patients treated with cranio-spinal
irradiation (16). Using the same delivery model, radiation volume
is virtually divided into numerous slices in dynamic raster scanning,
which are subdivided into voxel points. These slices are scanned
sequentially but continuously using the focused particle
pencil beam.
The steep dose gradients of IMPT, essential to achieve very
high dose conformality, are sensitive to range and setup
uncertainties, hence potentially affecting the quality of PT
delivered dose distributions. Those effects can be mitigated by
various techniques, the most effective ones being robust planningFrontiers in Oncology | www.frontiersin.org 3(17) and robust optimization (18). The radiation biological
characteristic of protons is also a concern in PT, where a
constant generic relative biological effectiveness (RBE) value of
1.1 is clinically used. It is anyway well known that RBE increases
with increasing Linear Energy Transfer (LET), thus presenting
with the highest value in the distal fall-off (19). As proton RBE
values are still associated with considerable uncertainties,
radiobiological evaluation of PT plans focus preferably on
linear energy transfer (LET), a physical parameter which can
be calculated quite accurately based on treatment planning
information. Adjustment of treatment fields’ direction or LET
optimization of PT plans can contribute to LET reduction in case
of high LET areas localized in critical structures. Research
developments in these areas of PT are likely going to further
increase its clinical benefits.PROTON THERAPY FOR WHO GRADE I
MENINGIOMA
Table 1 details the PT series delivered to WHO grade I
meningioma. Of note, approximately half (n = 237; 45.5%;
Table 1) of the meningioma patients were treated with eitherFIGURE 2 | Axial distributions for the (A) proton (IMPT) and (B) photon (VMAT) plans. In magenta and orange the isodoses lines of the pre irradiation (50% and
100% of 54 Gy respectively); (C) DVHs of the optic nerve right, chiasma, right temporal lobe and ROI defined within the 100% isodose line of the pre irradiation
(square markers for the proton plan and triangular markers for the photon plan). VMAT, Volumetric modulated Arc Therapy (photon plan); IMPT, Intensity Modulated
Proton Therapy (Proton plan).December 2020 | Volume 10 | Article 558845


















































































































⌂⌂Vlachogiannis et al. (20) 2017 170 ⌂13.0 [1–64] 84.0 14–
[21
El Shafie et al. (21) 2018 102 NR 46.8 50–
[50
Murray et al. (22) 2017 61 ∞ 21.4[0–547]○ 56.9 50.4–
[54
Noel et al. (23) 2005 51 NR 25.4 54–
[60
⌂⌂Halasz et al. (24) 2011 50 ∞ 2.1[0.3–9.7] 32 10.0–
[13
Slater et al. (25) 2012 47 ⌂27.6[1–224] 74.0 50.4–
Wenkel et al. (26) 2000 46 ∞ 32[2–243] 53.0 53.1–
[59
⌂⌂Vernimmen et al. (27) 2001 23 ⌂15.6[2.6–63] 40.0 54–6
17.3–
[20.









¥Total number of WHO grades I–III patients in cohort.
¶Stereotactic condition/radiosurgery/Hypo-fractionated PT, horizontal beam.
#Including but not limited to ocular adverse events, retinopathy and optic neuropathy.
ŧRadiological brain edema/biopsy proven brain necrosis/epilepsy.
∞Tumor volume.
⌂Target volume/Clinical target volume.
○WHO grades I and II.
⌂⌂Fractionated stereotactic proton therapy/proton radiosurgery.
Bold values provided are highlighting the overall results of patients numbers and outcome (Toxicity and tumor outcome).4
Weber et al. Managing Meningioma With Proton Therapyhypo-fractionated stereotactic PT (SFPT) or with proton
radiosurgery (pSRS). For non-SFPT/pSRS series, the Paul
Scherrer Institute recently published the results of 61 WHO
grade I meningioma patients treated with pencil beam scanning
PT to a median dose of 54 GyRBE (Table 1) (22). For those
patients progressing/recurring, most of them failed within the
treatment field. The estimated tumor local control (LC) and
overall survival (OS) was 95.7 and 92.1%, respectively (Table 1).
The difference in LC rates between benign and non-benign
tumors were significantly different (p <0.01) in this PT cohort.
Only 1/10 WHO grade I patients had a grade CTCAE 3 adverse
event during follow-up. Wenkel et al. reported on 46 WHO
grade I meningioma patients (median age, 50 years; range, 11–
74) treated with combined photon-proton radiotherapy (26).
The ratio of median photon and proton dose was 18.4%, but
some patients were treated with photon > proton doses
depending on the availability of the proton treatment unit on
the Harvard–Cambridge campus. Most tumors (29/46; 63%)
were treated for recurrence, either after subtotal (n = 19) or
gross total resection (n = 10). Only nine (20%) patients were
treated postoperatively with protons. Of note, the dose level
delivered by the Boston group is substantially higher (median, 59
GyRBE; Table 1) than other groups treating these patients with
protons worldwide. After a median follow-up of 53 months
(range, 12–207) the estimated recurrence-free- and OS were 88
and 77%, respectively. The 10-year toxicity-free survival was
80%. A substantial number of patients (4/46; 8.7%) presented
with visual/ocular toxicity (Table 1), and dosimetric analysis
revealed that these patients received a maximum median dose of
63.2, 67.5 and 67.4 GyRBE to the Chiasma, Optic nerve left- and
right, respectively. Of note, no patient died of progressive disease
but one patient died (CTCAE grade 5) of brain necrosis 22
months after therapy. Slater et al. reported another series on 72
skull-base WHO grade I-II meningioma and the outcome of 47
patients with benign tumors (25) was detailed in this paper. The
median total doses in the entire cohort for patients (age range, 9–
87 years) with and without histologic verification were 59 and 57
GyRBE (range, 50.4–66.6). With a median follow-up of 74
months (range, 3–83), the estimated 5-year LC was 99%.
Overall, 6 patients developed radiation induced toxicity, which
included visual adverse events (n = 3) and brain necrosis (n = 2).
The Heidelberg group reported on 102 skull-base histologically
proven (WHO grade I, n = 60) or image-defined meningioma
patients treated with proton therapy using the raster scanning
delivery paradigm (28). The median age of patients (80% female)
was 52 years (range 45–59) and after a median follow-up of 46.8
months, four local progressions were observed. As a result of the
small number of events, the median PFS was not reached. The
estimated 5-year PFS and OS were 96.6 and 96.2%, respectively
(Table 1). Three (2.7%) patients developed brain necrosis, of
which two were symptomatic, but no visual toxicity was
observed. Finally, another skull-base meningioma series was
published by the Orsay group in Paris reporting on the
outcome of 51 patients (42 females; 82.4%) (23). Forty-four
(86.3%) patients had histologically proven WHO grade I
meningioma and the median age of patients was 56 yearsFrontiers in Oncology | www.frontiersin.org 5(range, 11–75). The mean/median follow-up period was 25.4/
21.0 months with a range of 1–90 months and only local failure
was observed. The estimated 4-year LC and OS were 98 and
100%, respectively.
For the SFPT/pSRS series, the largest series originates from
the Uppsala group which reported the outcome of 170 WHO
grade I meningioma patients (mean age, 54.2 years; 22–85)
treated with hypo-fractionated (3–4 GyRBE per fraction) SFPT
delivered with a horizontal beam (20). Most of these benign
meningiomas (155/170; 86.1%) were skull base tumors in female
(135/170; 79.4%) patients treated with five fractions of 4 GyRBE,
due to the limited availability of the Gustav Werner cyclotron of
10 weeks annually. Median delivered dose was 21.9 GyRBE (14–
46). After a median follow-up of 84 months, the estimated 5- and
10-year progression-free survival rates were 93 and 85%,
respectively. Only 3 (1.7%) patients died of meningioma.
Radiation-induced adverse events were seen in 16 (9.4%)
patients, with pituitary insufficiency (37.5% of all toxicities)
being the most common. Brain radiation necrosis was
observed in 5 (2.9%) patients, most (4/5) being asymptomatic
(Table 1). Older patients and patients with tumors located in the
middle cranial fossa had a lower risk for tumor progression. The
Boston group has also been delivering pSRS for benign
meningioma and reported the outcome of these patients with a
median follow-up of 32 months (range, 6–133) (24). One
fraction of 10.0–15.5 GyRBE (median, 13.0) was delivered to
histologically proven or image-defined <4 cm (median volume,
2.1 cm3) meningiomas. Of note, atypical features were observed
in 6 (12%) patients but these features did not meet the criteria for
a diagnosis of atypical meningioma. Patients with tumor <2 mm
from the optic apparatus were not eligible for pSRS. In this series
from 2011, the estimated 3-year local tumor control was 94%.
Three (6%) patients presented with radiation-induced
complications, of which two were brain complications (Table
1). Finally, the South African group have reported the results of
23 WHO grade I skull-base meningioma patients (27). SFPT was
delivered either in three fractions with mean dose, 20.3 GyRBE to
18 patients. Noteworthy, 16 fractions or more, with a dose range
of 54.0–61.6 GyRBE, was delivered to another five patients.
Median volume of these meningiomas was 15.6 cm3. The
median follow-up time was 40 months (range, 13–69). For the
SFPT group, two local failures were observed and the estimated
5-year local control was 88%. No events were observed in the
fractionated group. One (3.7%) patient in the hypo-fractionated
group developed temporal lobe epilepsy.
These data show that protons can either be delivered
conventionally, with or without a pencil beam scanning
paradigm, or in stereotactic conditions (i.e. SFPT and pSRS). The
meningiomas treated with SFPT or pSRS were usually smaller than
their non-stereotactic PT counterparts, with a median tumor
volume reported in the three series listed in Table 3 of 13.0, 2.1
and 15.6 cm3, respectively. Interestingly, no increased toxicity
(visual toxicity or brain necrosis) was observed with SFPT/pSRS
when compared to PT (Table 1). Additionally, the outcome was
also identical, with the lowest PFS/RFS at 10 years of 85 and 88% for
SFPT/pSRS and PT, respectively (Table 1).December 2020 | Volume 10 | Article 558845
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II–III MENINGIOMA
The French group has reported on 24 patients (50% females)
with non-benign meningioma (atypical, n = 19; malignant, n = 5)
only treated with postoperative proton/photon therapy (29).
Most patients (n = 18; 75%) were treated after subtotal
resection to a mean/median total photon/proton dose of 65/68
GyRBE. After a median follow-up time of 32.2 months (range, 1–
72), 10 (41.7%) progression/recurrences were observed. The
mean RFS interval and estimated 5-year local tumor control
were 27.2 months and 46.5%, respectively. Noteworthy, survival
was significantly associated with dose, with a cut-off of 60
GyRBE. The relative risk of dying of meningioma was 8.3 (1.2–
57; p = 0.029) for those not treated at this dose level. One patient
developed radiation-induced necrosis 16 months after the
delivery of 68 GyRBE-Gy, of which 34 Gy was with photons
(Table 2). The Paul Scherrer Institute has also reported the
outcome of 33 grade II and 2 III meningioma patients treated
with protons only (22). The median administered dose was 62
GyRBE with a range of 54 to 68. The majority (9/14; 69%) of all
treatment failures from the meningioma cohort were non-benign
tumors. The estimated 5-year LC was these tumors was 68%. All
but 2 (8/10; 80%) in-field treatment failures were of WHO grade
II–III histology. Interestingly, only one brain necrosis (CTCAE
grade 3) occurred in a WHO grade II patients (Table 2), the
other brain necrosis (CTCAE grade 5) and brain edema occurred
in WHO grade I patients (Table 1). Out of the seven observed
visual toxicity, only one occurred in a WHO grade II
meningioma patient (Table 2). In the Heidelberg series (28),
all but two WHO grade II or III meningiomas were treated with
carbon ion therapy. The outcome of these two patients treated
with protons has not been reported separately. Hug et al.
reported on 16 patients treated with photon/proton therapy
(Table 2). These patients were included in the analysis of a
larger (n = 31) cohort of patients with non-benign histology
treated with high-dose photon and combined photon/proton
therapy (31). Interestingly, the local control of patients treated
with protons was significantly (p = 0.003) higher than those
treated with photons. The same statistical result (p = 0.025)
applied also for those treated at a dose of 60 GyRBE or higher,
regardless of the delivery of photons or protons/photons. In this
series, two patients developed symptomatic brain necrosis, one of
whom was treated with protons/photons to a dose of 72 Gy RBE
(Table 2). One last patient treated with 68.4 GyRBE combined
photon-proton therapy extensive visual field deficits and retained
no functional vision. Finally, Mac Donald et al. reported on 22
WHO grade II meningioma patients (30) treated with protons
only. Noteworthy, 6 patients had presumed radiation-induced
meningiomas. After a follow-up period of 7–104 months (mean,
39.2), five patients progressed/recurred. The estimated 5-year LC
was 71.1% (Table 2). The authors have seen the same impact on
radiation dose and patient’s outcome as did the French (29) and
other US (31) groups. The 5-year LC of those patients treated
with > and ≤60 GyRBE were 87.5 and 50%, respectively (p =
0.038). One symptomatic CTCAE grade III temporal lobeFrontiers in Oncology | www.frontiersin.org 6necrosis was observed (Table 2). No SFPT or pSRS delivery
was reported for non-benign meningiomas.RE-IRRADIATION WITH PROTON
THERAPY FOR RECURRENT
MENINGIOMA AFTER RADIOTHERAPY
The Heidelberg group reported on 42 recurring patients who
underwent prior RT for their meningioma (21). Compatible with
the treatment policy of this center, most meningioma patients
(34/42; 81%) were considered high-risk patients as a result of
tumor volume, WHO grading or individual patient’s history, and
were thus treated with carbon ion therapy. Only 8 (19%) patients
were retreated with PT. For the entire cohort, the median follow-
up time was 49.7, with a male/female gender ratio of 0.68. Most
patients had a WHO grade II (n = 25) or III (n = 6) recurring
tumor. Due to the limited number of patients, the analysis has
been made with the combined carbon ion therapy and PT
patients. The 1- and 2-year PFS were 71 and 56.5%,
respectively. The median PFS for all patients was 34.3 months.
Interestingly, the difference in PFS between WHO grades I and
II–III tumors was significant (p = 0.03). The estimated median,
1- and 2-year OS was 61 months, 89.6 and 71.4%, respectively.
Three (7.1%) patients presented with radiation-induced brain
necrosis. All these patients presented with WHO grade II (n = 1)
and III (n = 2) meningiomas and were retreated with 51 GyRBE
delivered with carbon ions after an initial photon dose delivery of
54, 60 and 60 Gy, respectively. Additionally, four patients (9.5%)
had worsening of their visual symptoms during follow-up.
Another series reported on the outcome of 16 recurring
meningioma (WHO grade I, seven; grade II, eight and WHO
grade 3, one) patients re-treated with PT (32). The median
photon and proton dose for the initial treatment and for the
re-irradiation was 54 Gy (range, 13–65.5) and 60 GyRBE (range,
30–66.6), respectively. After a median follow-up of 18.8 months
after PT, 7 (44%) intracranial recurrences/progression were
observed. The estimated 2-year RFS and OS were 43 and 94%,
respectively. Patients with benign recurring meningioma had a
significantly (p = 0.03) longer PFS than those with non-benign
tumors. Of note, the late high-grade toxicity was substantial.
Overall, 5 (31%) patients (median age, 72.9 years; range, 58.4–
75.1) with WHO grade II (n = 4) and I (n = 1) tumors presented
with late grade 3 toxicity, consisting of hydrocephalus (n = 3),
seizures (n = 1) and carotid stenosis with consequentially
cerebrovascular ischemia (n = 1). Three, one and one patients
received 60, 59.4 and 54 GyRBE proton dose respectively for
their re-treatment. No death resulting from this re-irradiation
with protons was observed.DISCUSSION
WHO grade I meningioma accounts for a substantial number of
primary brain tumors in adults and are the most prevalentDecember 2020 | Volume 10 | Article 558845


















































































Author #Ref Year #pts Median tumor∞/target
volume⌂(cm3)[range]
WHOgrade M
Murray et al. (22) 2017 35 ∞ 21.4[0–547] ○ II–III
Boskos et al. (29) 2009 24 ∞ 48.3[0–120] II–III
McDonald et al. (30) 2015 22 ∞ 8.1[0–89.3] II only
Hug et al. (31) 2000 16 NR II–III









¶Entire meningioma WHO grades I–III cohort.
#Mean dose/local control rate for WHO grades II and III, respectively.
ŧRadiological brain edema/biopsy proven brain necrosis/epilepsy.
ØMean follow-up interval for the photon only and photon/proton treatments.
∞Tumor volume.
⌂Target volume/clinical target volume.
○WHO grades I and II.
Bold values provided are highlighting the overall results of patients numbers and outcome (ToxicitT
y
Weber et al. Managing Meningioma With Proton Therapybenign primary neoplasm of the brain. RT has been used with
curative attempt in WHO grade meningioma patients whose
tumors are not amenable to surgery, for subtotally resected
(Simpson >III) tumors, for recurrent tumors or more rarely in
the adjuvant setting (33). This treatment modality is an
important component of the therapeutic armamentarium for
meningioma delivered to mostly elderly patients. However, RT
can result in a number of radiation-induced adverse events,
including but not limited to cognitive impairment, pituitary
dysfunction and secondary cancers. Regarding the former, a
systematic review of 11 published series assessing the impact of
surgery on the cognitive functioning of meningioma patients
observed that most of these patients suffer from deficits in several
cognitive domains comparative to the normative values (34).
Interestingly, surgery seemed to improve cognitive function in
most of these studies. Three series assessed the cognitive function
of meningioma patients undergoing RT after surgery. Most of
these studies (35, 36) but not all (37), showed that RT with or
without surgery had an impact on the patients’ visual, verbal and
working memory when compared to healthy controls, although
the specific cognitive impairment attributable to RT alone was
not assessed and no pre-treatment assessment of cognitive
function was performed, which are both major disclaimers in
the interpretation of these results. Nevertheless, it is safe to say
that any radiation modality that could decrease the likelihood of
cognitive impairment in elderly patients who are at risk of such a
complication would be advisable.
The precise position of the Bragg peak (38) within the
meningeal tumor has the possibility to decrease the dose
delivered to critical structures within the brain and to
decrease the overall brain integral dose. A recent dose
comparative planning study assessing photon and proton
therapy techniques for 20 meningioma >3 cm in size reported
a mean dose and brain volumes receiving intermediate
radiation dose (i.e. 20–30 Gy) approximately 50% lower (p
≤0.01) with intensity modulated PT (15). Additionally, the dose
delivered to 40% of the bilateral hippocampus was significantly
decreased by 74% in this study. These results are in line with
other studies (39). Dose comparison analysis of PT vs.
volumetric modulated arc photon radiotherapy have shownFrontiers in Oncology | www.frontiersin.org 8that integral doses were significantly (p <0.01) higher in all
photon plans with a reduction of approximately 50% with PT
(40). Substantial clinical evidence (41), while not unanimous
(42), supports the notion that radiation-induced injury to the
hippocampus may correlates with neurocognitive outcome of
patients who are treated with RT. As such, PT may decrease the
likelihood of long-term cognitive impairment and may be an
option for elderly meningioma patients who are at greater risk
of cognitive dysfunction or those younger patients with
pre-existing clinically relevant neurocognitive impairment
(Table 3).
The survival of benign meningioma patients is substantial and
secondary tumors may be observed after the delivery of adjuvant or
radical radiation therapy (44). As such, any therapeutic modality
that decreases the risk of radiation-induced tumors should be
offered when appropriate. Chung et al. compared the reduction of
secondary cancer risk in 558 pediatric and adult proton patients
with matched photon patients identified in the SEER database (45).
The observed secondary cancer incidence at 10 years was
significantly decreased from 8.6% with photons to 5.4% with
protons (Hazard ratio of 0.54; p <0.09). Importantly protons were
delivered to patients with a passive scattering delivery paradigm that
produced more neutrons than PBS (46, 47). The latter delivery may
thus produce even less radiation-induced malignancies. It is
noteworthy that the majority of meningioma patients managed
with protons have been treated with a passive scattering delivery
mode, as shown in Tables 1 and 2.
Radiation therapy is also a risk factor for developing
radiation-induced meningioma and other tumors, and have
been observed in 2.4–2.7% of patients in large case-series with
a long (i.e. 20 years) follow-up period (48, 49). The use of
conformal treatment such as PT may decrease the likelihood of
developing secondary neoplasms by decreasing the low-bath
dose delivered to the brain. The larger the meningioma is, the
highest would be the theoretical advantage, as suggested by other
authors (Table 3) (50, 51), for tumor induction and the
aforementioned cognitive toxicity of this treatment modality.
Theoretical tumor induction computations have shown in
children that protons significantly decrease the risk of this
unwanted complication (52), and the same effect has beenTABLE 3 | Indications for proton therapy in the management of WHO grades I–III meningioma.
Meningioma
(WHO grade)





I (Benign) Decrease in long term toxicity Should be considered if clinically available for
decreasing the probability of tumor induction
50.4–54 5 Bolsi et al. (43)
I (Benign) Decrease in long term toxicity Should be considered if clinically available for
decreasing the probability of cognitive impairment
50.4–54 5 Florijn et al. (15)
II–III (Atypical/
Malignant)
Dose escalation for tumor control Should be considered if clinically available >54.0 3b McDonald et al. (30), Hug
et al. (31), Boskos et al. (29)
Recurring (I–III) Tumor control and mitigate the risk of
radiation-induced adverse events
Should be considered if clinically available and
especially if:
* Non-elderly patient
* Initial Benign histology
* Previous irradiation at <60 Gy
≤60
(retreatment)
4 Imber et al. (32)
El Shafie et al. (21)December 2020*Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653.| Volume 10 | Article 558845
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a tumor-induction reduction of 50% with protons in a
computational study on benign meningioma (39).
That being said, the potential benefit of PT has to be weighed
against its substantial additional costs when compared to photon
radiotherapy (53). Over 500 WHO grade I or image-defined
meningioma have been treated with PT (Table 1). The clinical
results (5-year LC >95% and toxicity rates) appear to be in line
with the photon series. No cost effectiveness analysis has been
made so far for PT delivered to this benign tumor. Based on the
limited level of evidence (Table 3), PT can be considered for a
benign meningioma patients if volumetrically challenging or if
the patient has a higher risk of presenting radiation-induced
toxicity after treatment.
WHO grade II and III meningiomas are tumors with poorer
prognosis than benign meningiomas (54). Although the
incidence has been substantially increased with the new 2016
WHO meningioma classification, it is still considerably lower
than their benign counterparts. As such, the number of patients
treated with protons for non-benign meningioma is substantially
lower than for WHO grade I tumors by an order of 5 (Tables 1,
2). These former tumors, especially WHO grade III
meningiomas, show a local aggressive behavior, with or
without distant brain or non-brain failures (55, 56). Although,
the administration of radiation for WHO grade III tumors is
certain, the role of radiotherapy for WHO grade II tumors is less
clearly defined (57). Several survey have shown that only a
minority of centers would recommend RT after Simpson I–III
resection for WHO grade II meningioma (58). To address this
important question, a phase III intergroup trial (ROAM; EORTC
1308) has been activated in 2016 randomizing Simpson 1–3
WHO grade II meningioma patients between observation and
adjuvant RT delivering 59.4 Gy (59). This active study has an
accrual target of 190 patients and over 60% of the patients have
been currently accrued in this trial in Europe, Australia and
New-Zealand. A systematic survey of 10 studies of adjuvant RT
for grade II and III tumors showed that incomplete resection and
dose delivered of <50 Gy were associated with a poorer 5-year
PFS (60). Several retrospective analyses (Table 2) (29–31) of PT
series have shown that increasing the delivered radiation dose
may improve the patient outcomes. This parallels the experience
with photon series (61–63). These dose–response observations in
various analyses may validate the use of PT used with a dose-
escalation paradigm (Table 3). A recent prospective European
study (EORTC 22042-26042) has shown that the delivery of 60
Gy with photon-RT for Simpson I–III WHO grade II
meningioma was associated with substantial toxicity, as grade
3–4 adverse event were observed in 10.7 and 3.6% of patients,
respectively (64). This phase II-parallel non-randomized study
assessed also the efficacy of high-dose radiotherapy in three other
independent cohorts. Although the toxicity of the observational
study for Simpson IV–V tumors treated with 70 Gy using
photons has never been reported due to the small patients’
numbers, the toxicity of photon treatments at this dose level
was notable (Weber DC, personal communication). As such, if
moderate dose escalation is pursued, using the physicalFrontiers in Oncology | www.frontiersin.org 9advantage of the proton beam’s properties to conform the dose
deposition at a specific depth, the administration of PT in non-
benign meningioma should be considered (Table 3). This has
been the dose-strategy of all groups delivering PT for non-benign
meningioma with doses up to 72 GyRBE (median/mean, 62–68)
administered to these patients with no demonstrable increase the
reported toxicity (Table 2). The reported outcome after PT is
good, with a median 5-year LC of 52% for WHO grade II–III
tumors (Table 2) but caution should be exercised not to over-
estimate these results due to the small number (16–35; median
23) of patients and short follow-up intervals of those series
(Table 2). The level of evidence justifying the administration
of PT for non-benign meningioma, as with its benign
counterpart, is low (Table 3).
The management of recurring or progressing meningioma after
RT, especially high-grade tumors, is challenging. The therapeutic
strategy is often limited but salvage options may include additional
surgery and/or re-treatment with a radiation-modality such as
brachytherapy (65, 66), photon radiotherapy including but not
limited to normo- or hypo-fractionated radiotherapy/
radiosurgery, and PT (32). Systemic therapy, including the
administration of check-point inhibitors (67), is usually ineffective
and rarely translates into radiological objective responses, although
WHO grades II–III meningioma patients appear to benefit more
from chemotherapy than whose with grade I disease (5, 68). Re-
challenging these patients with radiation therapy again could
potentially cause serious radiation-induced adverse events, as the
organs at risk, including but not limited to the optic apparatus,
brainstem and cochlea, have received a substantial dose of radiation
already. As such, re-irradiation should be performed using highly
conformal radiation techniques. The dose-deposition of particle
therapy offers excellent sparing of organs at risk in direct vicinity of
the recurrent tumor (Figure 2). Dose comparison analysis of PT vs.
volumetric modulated arc photon radiotherapy have shown that
integral doses were significantly (p <0.01) higher in all photon plans
with a reduction of approximately 50% with PT (40) for recurring
meningioma treated with re-irradiation. Using these techniques
does not however nullify this risk, as illustrated in the Imber et al.
study which reported a >30% rate of high-grade late radiation
induced adverse events (32). Assessing the characteristics of these
patients with late toxicity, it seems that age (median age, 72.9 years)
and previous administered dose (median, 60 Gy) are important
factors to consider when assessing the possibility of re-irradiating
recurrent meningioma treated with prior RT with protons. Thus,
one should consider PT for re-irradiation of non-elderly patients
with recurring WHO grade I tumors treated previously with 50.4–
54 Gy of radiation (Table 3), as those have the highest PFS and the
lowest toxicity rates after re-irradiation. As for newly diagnosed or
recurrent meningiomas treated with upfront PT, with or without
surgery, the level of clinical evidence justifying the use of protons for
re-irradiation is low (Table 3).
Regarding patient outcomes, most series reporting the results
of PT for the management of WHO I and II–III tumors have
shown that the local tumor control or survival of non-benign
meningioma patients is lower than for patients with WHO grade
I tumors (Tables 1, 2). The Swiss group demonstrated that theDecember 2020 | Volume 10 | Article 558845
Weber et al. Managing Meningioma With Proton Therapy5-year LC rate was significantly lower (68 vs. 95.7%) for non-
benign meningiomas when compared to WHO grade I tumors
(22). This decrease in outcome-metrics is observed for non-
benign meningiomas, even when these challenging tumors are
treated with a dose-escalation paradigm (Table 2). This observed
trend mirrors the results of modern photon RT series that report
a PFS for atypical meningioma of approximately 70% (69). As
such, we must be aware of developing a zealotry about PT for
non-benign meningiomas and health providers must consider all
existing published evidence before advocating protons for the
management of these tumors. Possible explanation for this
finding include but are not limited to the referral bias of large/
recurrent tumors treated with PT, the span of multiple eras of
proton technology (passive scattering, pencil beam scanning,
intensity modulated PT, proton radiosurgery) and imbalances
between the photon and proton groups with respect to known
(age, gender, Simpson resection grade, tumor size, mitotic index)
(69–71) and unknown baseline prognostic factors. Additionally,
small patient numbers for this rare tumor and differences in
patient cohorts between the photon and proton series complicate
the interpretation of these findings.
PT is usually delivered to large and volumetrically complex
meningiomas. The mean largest volume in the WHO grade 1 PT
series is 193 cm3 (Table 1) and is usually larger than in photon
series. It may be highly appropriate to treat these challenging
patients with highly conformal radiation with a treatment
modality that decreases the integral brain dose. The radiosurgery
series have shown undisputedly that the largest the tumor volume is,
the highest the likelihood of observing a radiation-induced adverse
effect. A recent US series reporting on WHO grade I and II
meningiomas treated with radiosurgery, has shown that patients
who experienced cerebral edema were more significantly (p = 0–
028) likely present with larger tumors on univariate analysis (72).
These results are in line with other recent series (73–75). These
clinical data legitimate thus the use of protons for selected
meningioma patients with large tumors, especially if treated in a
dose-escalation paradigm.
Visual toxicity and/or brain necrosis are classical complications
of high-dose RT for the treatment of meningioma, too well known
to merit a repeat citation here. It is reassuring to observe that proton
series with a dose-escalation paradigm have not reported increased
toxicity to the optic apparatus or brain (Table 2), when compared to
photon series (76, 77). Taking the modern PT series, the observed
rate of visual or brain toxicity is 0–1.5 and 2.9–4.5%, respectively
(Table 2). In these PT series, radiation-induced toxicity was usually
observed when the dose constraints were relaxed, such as those
patients treated with 63.2–67.4 GyRBE to the optic apparatus (26).
It is important however to note that adverse events occur with
photon or proton radiation even when the dose constraints are
consciously met and when the patient has no risk factors (76). In the
Swiss series, the only grade 5 brain necrosis occurred in a WHO
grade I patient treated with 54 GyRBE with all dose-constraints met.
In the same series, the two optic nerve and the two other
retinopathy observed were also planned respecting all optic
apparatus dose constraints. Regarding the toxicity on these organs
at risk, several groups have tried to identify dose metrics predictiveFrontiers in Oncology | www.frontiersin.org 10of clinically relevant toxicity (78–82) but the results are not robust
and the implementation of these constraints is problematic in some
patients with WHO grade II or III tumors. Care should be taken
that patients should be aware of these rare adverse events in the
informed consent process that should adhere to national guidelines.
Our review has a number of limitations that future studies
should address. Firstly, all reviewed data are retrospective in
nature and are thus subject to a known and unknown biases that
have been only partially discussed in this section of the
manuscript. The reviewed data lacked prospectively captured
patient-reported outcomes and quality of life that are important
in the area of modern neuro-oncology. PSI will submit soon the
analysis of the QoL of meningioma patients treated with protons
using the EORTC C30 and BN20 questionnaires. These data will
also enhance substantially our understanding of how exactly PT
may distinguish itself clinically from other radiation modalities.
Prospective cohort studies from other institutions will greatly
benefit our understanding of meningioma patient outcomes
treated with protons and are arguably required at this juncture
in time. The concept of an international prospective registry,
such as the one proposed by the European Particle Therapy
Network in its Clinical Work-package 1 (83), performed under a
standardized protocol is immeasurably desirable, for it will allow
more homogenous data to accumulate from multiple European
experiences. These could then bolster our ability to perform
more robust bias assessments, assess the true value of protons for
this indication and justify any decision-algorithms, with or
without cost–benefit analyses. Finally, the relatively short
follow-up time and more importantly the limited number of
patients in the cohorts limit somehow the generated level of
evidence, especially so for secondary malignancies.CONCLUSIONS
The delivery of PT for the treatment of intracranial meningioma
may be discussed in clinical settings including but not limited to
volumetrically challenging tumors, non-benign histology or for the
re-irradiation of recurring/progressive tumors. Patient with a high-
risk of radiation induced toxicity may also benefit from the decrease
of dose delivered to critical structures such as the optic apparatus
and the brain. The outcome of approximately 500 WHO grade I
meningioma patients have been reported with excellent tumor
control rates and rare radiation-induced adverse events. For
WHO grade II–III meningiomas treated with a dose-escalation
paradigm, the toxicity profile is clinically acceptable. Re-irradiation
of progressing/recurring tumors with protons should be discussed
on a case to case basis and should be limited to those younger
patients with benign tumors that should most benefit from protons.AUTHOR CONTRIBUTIONS
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